HDPCR for Minimal Residual Disease (MRD)
Oncology
Key Facts
About ChromaCode
ChromaCode is a private diagnostics company commercializing its High-Definition PCR (HDPCR™) technology, a platform that significantly expands the multiplexing capability of standard digital PCR. By using amplitude modulation and spectral encoding of standard TaqMan probes paired with its ChromaCode Cloud analytics software, the company aims to provide NGS-level genomic content with the speed, simplicity, and lower cost of PCR. Its initial focus is on oncology applications, including tumor profiling and minimal residual disease (MRD) testing, targeting a large market opportunity by enabling labs to increase throughput and margins. The company appears to be in an early revenue stage, leveraging a reagent kit and software-as-a-service business model.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |